Tags

Type your tag names separated by a space and hit enter

Tocilizumab in Sars-cov-2 Patients with the Syndrome of Cytokine Storm; a Narrative review.
Rev Recent Clin Trials. 2020 Sep 17 [Online ahead of print]RR

Abstract

INTRODUCTION

Coronavirus is a group of viruses which causes diseases in mammals and birds. In humans, these family of viruses can cause the respiratory infections from mild form to fatal forms. It is preferably called as coronavirus. Formally it known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or 2019 novel coronavirus (2019- nCoV) and this disease is called as coronavirus disease 2019 (COVID-19). SARS-CoV-2 is infectious in humans and world health organization has announced that Covid-19 as a pandemic disease. Tocilizumab is a biological agent which inhibits the cytokine, interleukin 6 (IL-6 inhibitor). As SARS-CoV-2 infection leads to the development of cytokine storm syndrome, the drug tocilizumab seems to have positive effect in patients with covid-19.

PURPOSE OF THE STUDY

To analyze and review the possible effects and efficacy of the tocilizumab (monoclonal antibody against IL-6 receptors) in SARS-CoV-2 patients.

MATERIALS AND METHODS

The search strategy on recent research and review articles is used for the SARS-CoV-2 disease and their characteristics. Furthermore we have analyzed most recent research article on monoclonal antibody against IL-6 receptors (tocilizumab) and their possible clinical effects in Covid-19 and their clinical trials on Covid-19 patients.

RESULTS AND CONCLUSION

Covid-19 is a disease caused by SARS-CoV-2 infection. It is a life threatening condition which can give rise to fatal outcomes if left untreated. However there are no approved treatment for covid-19 globally. Furthermore we can conclude that SARS-CoV-2 is associated with worsening of lung conditions characterized by interstitial pneumonia with acute respiratory distress syndrome as a result of cytokine storm syndrome. According to available research data tocilizumab, a recombinant humanized anti-human monoclonal antibody of IgG1τ (gamma 1, kappa) can improve patient's condition from cytokine storm syndrome by inhibiting the IL-6 (Interleukin 6) receptors. The rational use of the tocilizumab in severe and critically ill covid-19 patients can prevent the development of irreversible lung injury and death of the patient. Three retrospective studies of Xiaoling Xu et al., Pan luo et al. and Paola Tonaiti et al. has shown the efficacy of tocilizumab in severe and critically ill covid-19 patients. However we need more randomized research studies with significant number of patients which can confirm the promising results on tocilizumab treatment in covid-19 patients and even ongoing clinical trails such as TOSCA, COVACTA results has not been published yet which are expected to give better and more significant results on tocilizumab's effectiveness and safety.

Authors+Show Affiliations

Department of Internal Medicine No.2, V.I. Vernadsky Crimean Federal University, Simferopol. Russian Federation.Department of Internal Medicine No.2, V.I. Vernadsky Crimean Federal University, Simferopol. Russian Federation.Department of Internal Medicine No.2, V.I. Vernadsky Crimean Federal University, Simferopol. Russian Federation.Science Research Department, Alexander Muss Institute for Israel Education (AMIIE), Hod Hasharon. Israel.Clinical Nutrition Unit and Internal Medicine Unit, Madonna del Soccorso General Hospital, Via Luciano Manara 7, 63074 San Benedetto del Tronto (AP). Italy.Department of Health Sciences, Magna Graecia University, Catanzaro. Italy.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32940187

Citation

Kulanthaivel, Shanmugaraj, et al. "Tocilizumab in Sars-cov-2 Patients With the Syndrome of Cytokine Storm; a Narrative Review." Reviews On Recent Clinical Trials, 2020.
Kulanthaivel S, Kaliberdenko VB, Balasundaram K, et al. Tocilizumab in Sars-cov-2 Patients with the Syndrome of Cytokine Storm; a Narrative review. Rev Recent Clin Trials. 2020.
Kulanthaivel, S., Kaliberdenko, V. B., Balasundaram, K., Shterenshis, M. V., Scarpellini, E., & Abenavoli, L. (2020). Tocilizumab in Sars-cov-2 Patients with the Syndrome of Cytokine Storm; a Narrative review. Reviews On Recent Clinical Trials. https://doi.org/10.2174/1574887115666200917110954
Kulanthaivel S, et al. Tocilizumab in Sars-cov-2 Patients With the Syndrome of Cytokine Storm; a Narrative Review. Rev Recent Clin Trials. 2020 Sep 17; PubMed PMID: 32940187.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tocilizumab in Sars-cov-2 Patients with the Syndrome of Cytokine Storm; a Narrative review. AU - Kulanthaivel,Shanmugaraj, AU - Kaliberdenko,Vitalii B, AU - Balasundaram,Keerthanaa, AU - Shterenshis,Michael V, AU - Scarpellini,Emidio, AU - Abenavoli,Ludovico, Y1 - 2020/09/17/ PY - 2020/05/19/received PY - 2020/07/15/revised PY - 2020/08/11/accepted PY - 2020/9/17/entrez PY - 2020/9/18/pubmed PY - 2020/9/18/medline KW - SARS-CoV-2 KW - acute respiratory distress syndrome KW - covid-19 KW - cytokine release syndrome KW - cytokine storm KW - interleukin 6 (IL-6) KW - interstitial pneumonia. KW - tocilizumab JF - Reviews on recent clinical trials JO - Rev Recent Clin Trials N2 - INTRODUCTION: Coronavirus is a group of viruses which causes diseases in mammals and birds. In humans, these family of viruses can cause the respiratory infections from mild form to fatal forms. It is preferably called as coronavirus. Formally it known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or 2019 novel coronavirus (2019- nCoV) and this disease is called as coronavirus disease 2019 (COVID-19). SARS-CoV-2 is infectious in humans and world health organization has announced that Covid-19 as a pandemic disease. Tocilizumab is a biological agent which inhibits the cytokine, interleukin 6 (IL-6 inhibitor). As SARS-CoV-2 infection leads to the development of cytokine storm syndrome, the drug tocilizumab seems to have positive effect in patients with covid-19. PURPOSE OF THE STUDY: To analyze and review the possible effects and efficacy of the tocilizumab (monoclonal antibody against IL-6 receptors) in SARS-CoV-2 patients. MATERIALS AND METHODS: The search strategy on recent research and review articles is used for the SARS-CoV-2 disease and their characteristics. Furthermore we have analyzed most recent research article on monoclonal antibody against IL-6 receptors (tocilizumab) and their possible clinical effects in Covid-19 and their clinical trials on Covid-19 patients. RESULTS AND CONCLUSION: Covid-19 is a disease caused by SARS-CoV-2 infection. It is a life threatening condition which can give rise to fatal outcomes if left untreated. However there are no approved treatment for covid-19 globally. Furthermore we can conclude that SARS-CoV-2 is associated with worsening of lung conditions characterized by interstitial pneumonia with acute respiratory distress syndrome as a result of cytokine storm syndrome. According to available research data tocilizumab, a recombinant humanized anti-human monoclonal antibody of IgG1τ (gamma 1, kappa) can improve patient's condition from cytokine storm syndrome by inhibiting the IL-6 (Interleukin 6) receptors. The rational use of the tocilizumab in severe and critically ill covid-19 patients can prevent the development of irreversible lung injury and death of the patient. Three retrospective studies of Xiaoling Xu et al., Pan luo et al. and Paola Tonaiti et al. has shown the efficacy of tocilizumab in severe and critically ill covid-19 patients. However we need more randomized research studies with significant number of patients which can confirm the promising results on tocilizumab treatment in covid-19 patients and even ongoing clinical trails such as TOSCA, COVACTA results has not been published yet which are expected to give better and more significant results on tocilizumab's effectiveness and safety. SN - 1876-1038 UR - https://www.unboundmedicine.com/medline/citation/32940187/Tocilizumab_in_Sars_cov_2_Patients_with_the_Syndrome_of_Cytokine_Storm L2 - https://www.eurekaselect.com/185978/article DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.